Chromatin conformation has a fundamental role in regulating gene transcription and silencing as well as DNA repair 1 . In response to stress, the p53 protein triggers cell cycle arrest and/or apoptosis [2] [3] [4] . p53 physically interacts with several transcriptional coactivators and co-repressors, which have intrinsic histone-modifying activities 5, 6 , and also with histone deacetylase complexes that act specifically to remodel chromatin 7, 8 . In addition, several subunits of the SWI/SNF ATP-dependent chromatin remodeling complex are either recruited onto p53 target promoters or interact with p53 itself 9-11 , suggesting their role in p53-mediated transactivation.
a r t i c l e s
Chromatin conformation has a fundamental role in regulating gene transcription and silencing as well as DNA repair 1 . In response to stress, the p53 protein triggers cell cycle arrest and/or apoptosis [2] [3] [4] . p53 physically interacts with several transcriptional coactivators and co-repressors, which have intrinsic histone-modifying activities 5, 6 , and also with histone deacetylase complexes that act specifically to remodel chromatin 7, 8 . In addition, several subunits of the SWI/SNF ATP-dependent chromatin remodeling complex are either recruited onto p53 target promoters or interact with p53 itself [9] [10] [11] , suggesting their role in p53-mediated transactivation.
The N-terminal tails of histones undergo post-translational modifications, including methylation, acetylation, phosphorylation, ubiquitination, sumoylation, biotinylation and ADP ribosylation [12] [13] [14] [15] . p53 has also been shown to influence histone H3 acetylation at Lys9 (H3K9Ac) and Lys14 (H3K14Ac) 16, 17 , although the mechanism for this is not known. Post-translational modifications such as acetylation alter chromatin structure by changing internucleosomal contacts, whereas others such as methylation serve to create docking sites for effector proteins, leading to distinct biological outcomes 18 . Five lysines on histone H3 (Lys4, Lys9, Lys27, Lys36 and Lys79) and one lysine on histone H4 (Lys20) can undergo methylation by specific histone methyltransferases (HMTases) 13 . Each of these lysine residues can be mono-, di-and trimethylated in vivo, adding further layers of combinatorial control. For example, H3K4me3 is usually associated with the transcriptional start sites of active genes, whereas mono-or dimethylated H3K4 is localized to the middle and ends of genes 19 . By contrast, H3K9me1 and H3K9me2 are mainly localized to silent domains within euchromatin, and H3K9me3 is generally localized to constitutive heterochromatin 20 .
In the present study, we demonstrate that SUV39H1, which writes the H3K9me3 chromatin mark, is a repression target of p53. We show that the promoters of several of the p53 established target genes are enriched with this mark in an uninduced state. SUV39H1 downregulation reduces H3K9me3 on these promoters, thereby enhancing p53 promoter occupancy and contributing to the activation of p53 target genes and the p53-induced apoptotic response. Thus, our findings uncover a new layer of regulation at the chromatin level, in which p53 modulates the histone methylation of its target promoters.
RESULTS p53 downregulates SUV39H1 expression
We hypothesized that p53 may influence chromatin-modifying enzymes that have crucial roles in altering the chromatin template to render it suitable for p53-dependent transcription. A tetracyclineregulated EJ-p53 expression system 21 has been used to generate a cDNA expression array to analyze p53-modulated genes and to identify several new p53 targets 22, 23 . By mining this same cDNA expression array (unpublished data), we observed a decrease in RNA levels of SUV39H1, an HMTase that catalyzes the H3K9me3 heterochromatin mark 24, 25 , in response to p53 induction. Upregulation of p53 by various methods in several cell lines of different tissue origin led to decreased RNA and protein levels of SUV39H1 ( Fig. 1 and  Supplementary Fig. 1a) . Known p53 transcriptional targets p21, PIG3 and MDM2 (refs. 26-28) served as positive controls (Fig. 1a, b,e and Supplementary Fig. 1a) . To examine the specificity of SUV39H1 downregulation in response to p53 induction, we generated B5/589 cells that stably express short hairpin RNA (shRNA) directed against p53. Control cells, but not those expressing sh-p53, showed a reduction in SUV39H1 RNA level upon MI-219 treatment ( Supplementary  Fig. 1b) . Further, this decrease in SUV39H1 RNA expression was observed in U87MG (WT p53) cells, but not in U373MG cells (R273H mutant p53), under the same conditions (Supplementary Fig. 1c) .
p53 has been shown to repress the expression of several genes, including survivin, stathmin, CDC25C, cyclin A2 and cyclin B1 (refs. 29-34) . Although these genes have all been found to have p53 binding sites on their promoters, subsequent studies have shown that in the absence of p21, p53 was unable to repress their expression. Moreover, ectopic expression of p21, in the absence of p53, was able to repress these same genes 35 . Although we observed p53 binding on the SUV39H1 promoter in EJ-p53 and B5/589 cells when induced for p53, we failed to observe such promoter occupancy in HCT116 WT cells (data not shown). Thus, we investigated the role of p21 in p53-mediated transcriptional repression of SUV39H1. We observed a similar decrease in SUV39H1 RNA expression in both EJ-p53 and EJ-p21 cells, when induced for p53 or p21, respectively (Fig. 1c) . Further, p53 was unable to downregulate SUV39H1 transcript levels in EJ-p53 cells silenced for p21 (Fig. 1d) . In EJ-p53 sh-GFP cells, an increase of two-fold and nine-fold in p53 level decreased SUV39H1 expression by 70% and 55%, respectively, whereas in EJ-p53 sh-p21 cells, a two-fold and six-fold increase in p53 level failed to reduce the expression of SUV39H1 at all. These results establish that p21 is both necessary and sufficient for p53-mediated SUV39H1 transcriptional downregulation, suggesting a potential involvement of an RB-E2F-dependent mechanism.
The p53 transcriptional target MDM2 has recently been reported to bind SUV39H1 and cause its proteosomal degradation 36 . Confirming these findings, we observed increased SUV39H1 ubiquitination in response to p53 activation (Supplementary Fig. 1d ). Moreover, downregulation of SUV39H1 protein expression in response to p53 induction was inhibited when cells were treated with the proteosomal inhibitor MG-132 (Supplementary Fig. 1e) . Further, exogenous expression of MDM2 resulted in a decreased protein level of exogenously expressed SUV39H1 in the absence of p53 ( Supplementary  Fig. 1f ), and this decrease was rescued in the presence of MG-132 (Supplementary Fig. 1f) . All of the above findings indicate that p53 also downregulates SUV39H1 expression at the protein level by MDM2-mediated proteosomal degradation. Further, p53 induction led to a rapid and sustained decrease in SUV39H1 protein level, a r t i c l e s npg a r t i c l e s whereas tet-regulated induction of p21 led to a comparable but less rapid decrease in the SUV39H1 protein level in the absence of any detectable MDM2 expression (Fig. 1e) . Thus, p53 uses different mechanisms to downregulate SUV39H1 expression through two independent target genes, p21 and MDM2.
Induction of p53 abrogates the H3K9me3 heterochromatin mark
There is redundancy in the functions of remodeling factors that induce permissive alterations in chromatin accessibility 37 , whereas SUV39H1 is the only ubiquitously expressed HMTase that adds the repressive H3K9me3 mark 38 . Thus, we analyzed the effect of p53 activation on H3K9me3 levels and observed decreased levels of this mark in EJ-p53 (Fig. 2a) , B5/589 (Fig. 2b) and HCT116 p53 WT cells (Fig. 2c ) in response to p53 induction. Further, we did not observe a decrease in the H3K9me3 mark in either B5/589 cells stably transduced with sh-p53, when treated with MI-219 (Fig. 2b) , or in HCT116 p53 −/− cells treated with increasing doses of doxorubicin (Fig. 2c) . Of note, the levels of H3K9me1 and H3K9me2 remained unaffected, confirming the specificity of the p53-induced decrease in H3K9me3 levels (data not shown).
To investigate how alterations in the H3K9me3 mark might affect p53 function, we analyzed the relative enrichment of trimethylated H3K9 on p53 target promoters in response to p53 activation. Chromatin immunoprecipitation (ChIP) analysis with anti-H3K9me3 antibody showed the presence of this histone mark on each of the p53 target promoters analyzed in untreated B5/589 or uninduced EJ-p53 cells. H3K9me3 occupancy was reduced in each case upon p53 induction in both cell lines (Fig. 2d and data not shown) . Furthermore, we observed a decrease in the H3K9me3 mark on these promoters as early as 6 h following p53 induction by MI-219 treatment in B5/589 cells (Supplementary Fig. 2a ). This decrease correlated well with increased p53 occupancy on the same promoters (Supplementary Fig. 2a) .
Overexpression of SUV39H1 inhibits p53-dependent apoptosis
To investigate the role of this repressive heterochromatin mark in p53-induced cell fate decisions, we exogenously overexpressed SUV39H1 in HCT116 WT as well as in B5/589 cells. B5/589 and HCT116 WT cells stably expressing SUV39H1 showed ~3.2-fold and ~4-fold greater SUV39H1 expression levels, respectively, than cells that stably express the vector. This abrogated the reduction in SUV39H1 and H3K9me3 expression levels that was induced by p53 activation in cells (Fig. 3a and data not shown) as well as the level of the H3K9me3 mark present on each of the p53 target promoters that were analyzed (Fig. 3b) . p53 was less efficient in inducing its target genes in cells overexpressing SUV39H1, as observed at both RNA (Fig. 3c) and protein levels (Fig. 3a) . The reduced ability of p53 to transactivate its target genes was consistent with reduced p53 occupancy on its target promoters under conditions of SUV39H1 overexpression (Fig. 3d) , even though the extent of p53 activation was similar to that in control cells ( Fig. 3a and Supplementary Fig. 2c ). Finally, we observed a reduced ability of p53 to induce apoptosis, as determined by propidium iodide staining in SUV39H1-overexpressing cells (Fig. 3e) . The relative reduction in apoptosis was decreased at higher etoposide concentrations, which is associated with a decreased ability to sustain overexpressed SUV39H1 protein levels at higher levels of p53-MDM2 a b 
induction (data not shown). We also observed reduced expression at both RNA and protein levels of the CDK inhibitor p21, which is both necessary and sufficient for p53-induced growth arrest 26, 39 (Fig. 3a,c) , together with reduced p53 promoter occupancy (Fig. 3d) . However, we did not observe any major decrease in p53-induced cell cycle arrest in cells overexpressing SUV39H1 (Supplementary Fig. 2b ).
SUV39H1 silencing causes p21-dependent cell cycle arrest
To assess the impact of SUV39H1 silencing on p53 target gene expression, we generated HCT116 WT and B5/589 cells stably expressing inducible SUV39H1 shRNA. Doxycycline induction ( Supplementary  Figs. 3a and 4a) led to a decrease in both SUV39H1 RNA (Fig. 4 and Supplementary Fig. 3d ) and protein levels ( Fig. 4c and Supplementary  Fig. 4b ). We observed a resulting reduction of H3K9me3 in total protein lysates ( Fig. 4c and Supplementary Fig. 4b ) as well as a reduction of the H3K9me3 mark on each of the p53 target promoters tested (Fig. 4b) . We observed no detectable alteration in the expression level of any p53 proapoptotic transcriptional target analyzed or evidence of an apoptotic response under conditions of SUV39H1 silencing (Fig. 4a,e) .
A previous study indicated that SUV39H1 knockdown was associated with increased p21 RNA expression 40 . We confirmed increased expression of p21 at both RNA ( Fig. 4a and Supplementary Fig. 3d ) and protein levels ( Fig. 4c and Supplementary Fig. 4b ) in response to sh-SUV39H1 induction. Moreover, this response appeared to be independent of p53, as there was no detectable change in p53 RNA (Supplementary Fig. 3d ) or protein levels (Fig. 4c) . Of note, this modest increase in p21 was sufficient to cause cell cycle arrest, as determined by propidium iodide staining ( Fig. 4e and Supplementary  Fig. 4c ) and colony-forming ability (Fig. 4d and Supplementary  Figs. 4d and 5a ) in both HCT116 WT and B5/589 cells. To rigorously exclude any p53-dependent contribution, we expressed inducible sh-SUV39H1 in HCT116 p53 −/− cells (Supplementary Fig. 3b ) and observed similar p21 induction (Supplementary Fig. 3e ) associated with cell cycle arrest and colony suppression ( Fig. 4e and  Supplementary Fig. 5a ). Thus, unlike the case with p53 pro-apoptotic target genes, loss of SUV39H1 expression removes the barrier to p21 expression, presumably allowing recruitment of transcription factors already present in the cell or induced by SUV39H1 silencing. 
r t i c l e s
To directly establish that p21 is both necessary and sufficient for SUV39H1 knockdown-dependent cell cycle arrest, we generated inducible sh-SUV39H1 HCT116 p21 −/− cells 39 ( Supplementary  Fig. 3c ) and observed that SUV39H1 silencing failed to induce cell cycle arrest and colony suppression in these cells (Fig. 4e and  Supplementary Fig. 5a ). We also generated double knockdown stable cells with sh-p21 and inducible sh-SUV39H1 in HCT116 WT cells (Supplementary Fig. 5b) . Induction of sh-SUV39H1 led to cell cycle arrest in HCT116 WT cells but not in HCT116 cells silenced for p21 (Supplementary Fig. 5c,d) . Furthermore, silencing of SUV39H1 cooperated with p53 in inducing p21 at both RNA (Fig. 5) and protein levels (Supplementary Fig. 6a ) but did not result in enhanced cell cycle arrest (Supplementary Fig. 6b,c) . Thus, SUV39H1 silencing, like overexpression, did not detectably influence p53-dependent cell cycle arrest (Supplementary Figs. 2b and 6) , presumably because of the low threshold of p21 required to induce cell cycle arrest in the cells analyzed.
SUV39H1 pre-silencing enhances p53-dependent apoptosis
To test the effects of a low basal level of SUV39H1 expression on p53-induced apoptosis, we first silenced SUV39H1 in WT p53-containing HCT116 cells. Both etoposide, a topoisomerase II inhibitor 41 , and paclitaxel, which interferes with the normal breakdown of microtubules during cell division 42 , induced considerably increased apoptosis under these conditions, as analyzed by propidium iodide staining (Fig. 5a, Supplementary Fig. 7a and data not shown) and Annexin-V staining (Supplementary Fig. 7b ). This enhancement of chemotherapy-induced apoptosis was p53 dependent, as we did not observe any such cooperation in HCT116 p53 −/− cells ( Fig. 5a and Supplementary Fig. 7a) npg a r t i c l e s WT cells was associated with increased expression of p53 proapoptotic target genes, as measured at both RNA (Fig. 5b) and protein levels (Fig. 5c ) in the absence of any noteworthy difference in p53 expression levels. In addition, increased p53 target gene expression was associated with increased p53 promoter occupancy (Fig. 5d) . All of these findings argue that low basal SUV39H1 levels influence the chromatin conformation of p53 pro-apoptotic target genes, making their promoters more accessible and enhancing the p53 apoptotic response to chemotherapy. SUV39H1 is known to influence global gene expression 43 . Thus, we carried out micrococcal nuclease (MNase) assays in EJ-p53 cells with and without p53 induction. p53 activation led to increased sensitivity to MNase treatment, as measured by increased DNA laddering, consistent with induction of a more relaxed chromatin structure (Supplementary Fig. 8a) . We also analyzed the expression of several genes not known to be p53 transcriptional targets but reported to be targets of SUV39H1 (ref. 44) . We confirmed that RNA expression levels of growth hormone receptor (GHR), myostatin (GDF8), scinderin (SCIN) and ets homologous factor (EHF) were upregulated in SUV39H1-silenced cells (Supplementary Fig. 8b ). Similar gene expression changes were also observed in EJ-p53 cells upon p53 induction (Supplementary Fig. 8c ). All of these results argue that SUV39H1 regulates the transcription of genes in addition to p53 direct targets. Further studies will be necessary to determine whether-and if so, how-these more global effects mediated by p53 repression of SUV39H1 influence p53 signaling.
DISCUSSION
Our present study demonstrates the ability of the p53 tumor suppressor protein to influence its own transcriptional program by downregulating the expression of SUV39H1, the histone code writer of the H3K9me3 mark. We identified the presence of the H3K9me3 repressive histone modification on several p53 target promoters. By inducing a decrease in this mark through downregulation of SUV39H1 expression, p53 causes a more 'open' chromatin conformation that allows increased p53 promoter occupancy and contributes to the activation of p53 target genes and the p53-induced apoptotic response.
Our results indicate that p53 regulates SUV39H1 expression at the RNA level by p21-mediated transcriptional downregulation and at the protein level by MDM2-mediated proteosomal degradation. p53 was unable to downregulate SUV39H1 transcript levels in cells silenced for p21. Furthermore, p21 was itself able to downregulate SUV39H1 RNA levels independently of p53. These data suggest that the cell cycle has a role in this repression and that the mechanism may involve the RB-E2F pathway. In fact, we observed putative E2F binding sites on the SUV39H1 promoter using MatInspector (http://www.genomatix.de/). Currently, we are analyzing the relative role of different E2F family members in p53-mediated downregulation of SUV39H1 transcription. The reduction in levels of SUV39H1 in HCT116 WT cells was modest when compared to that observed in EJ-p53 cells. However, there was a marked decrease in H3K9me3 levels in HCT116 WT cells compared to EJ-p53 cells (compare Fig. 2a with Fig. 2c) . Furthermore, SUV39H1 silencing alone was sufficient to reduce the levels of H3K9me3 on p53 target promoters, even without the activation of p53 (Fig. 4b) . These results imply that there must be a dynamic equilibrium between the 'erasers' of this mark and SUV39H1, such that a change in the balance as a result of SUV39H1 silencing was sufficient to remove the H3K9me3 repressive chromatin mark.
The transforming adenovirus E1A and E1B proteins are well known to inactivate RB and p53 functions, respectively 45 . Recent studies have identified another adenoviral protein, E4-ORF3, which causes an increase in the H3K9me3 mark at p53 target promoters through a mechanism presumed to involve SUV39H1 function 46 . Evidence that E4-ORF3 can replace the need for E1B function in overcoming the host's p53 response strongly suggests that epigenetic regulation of the H3K9me3 mark has a major impact on p53 function. Our complementary findings establish that SUV39H1 is a p53 repression target that has a critical function in determining p53 cell fate decisions, through modulation of the H3K9me3 mark (Fig. 5e) . Evidence that p53 exerts redundant mechanisms to silence SUV39H1 epigenetic function further argues (Fig. 5e) for the importance of SUV39H1 silencing in the p53 response.
Recently, increased binding of exogenously expressed SUV39H1 to the p21 promoter in the presence of exogenously expressed p53 and either exogenously expressed or amplified MDM2 has been reported 47 . Although this study observed increased levels of the H3K9me3 mark at the p21 promoter under these conditions of exogenous protein expression, we demonstrated decreased levels of this mark in response to p53 activation under physiological conditions. It was also reported that p53 induction in the presence of SUV39H1 knockdown resulted in increased p21 RNA levels, consistent with our findings and with what might be expected for loss rather than gain of the H3K9me3 repressive mark. This same group further found that SUV39H1 binding to the MDM2 acidic domain allows the p53-MDM2-SUV39H1 complex to bind DNA 48 . More recent evidence that MDM2 acts as a ubiquitin ligase that binds SUV39H1 as well as p53 and targets both proteins for proteosomal degradation 36 could also explain the presence of all of these proteins at the p21 promoter.
Misregulation of various histone modifications has been observed in human cancers [49] [50] [51] . Loss of SUV39H1 function sensitizes mice to tumorigenesis 43 . Furthermore, reduced levels of H3K9me3 are associated with genomic instability 43 . By contrast, colorectal tumors show increased SUV39H1 expression levels 52 . Our present studies demonstrate that variations in basal levels of SUV39H1 have a major impact on p53 pro-apoptotic signaling by altering levels of the H3K9me3 mark, uncovering a new layer of regulation at the chromatin level by p53 modulation of histone methylation of its target promoters. Thus, normal cells with low basal levels may have an increased sensitivity to p53-induced apoptosis relative to otherwise comparable cells. Conversely, WT p53-containing cancer cells possessing high steadystate levels of SUV39H1 may be more resistant to chemotherapy and irradiation therapy than otherwise comparable tumor cells expressing low SUV39H1 levels.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nsmb/.
